GlassScriptPhysician profile
Neil K Sinha
NPI 1427213826
$4,040.78
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $654 · 2021: $1,231 · 2022: $883 · 2023: $766 · 2024: $86.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $852.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $980.13 | 2021-2024 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $564.44 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $421.39 | 2019-2022 | |
| Vertos Medical, INC. | $258.62 | 2022-2023 | Mild Device Kit |
| Merck Sharp & Dohme LLC | $200.24 | 2019-2023 | Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $180.77 | 2020-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $167.77 | 2019-2022 | |
| Pfizer INC. | $157.34 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $119.26 | 2021 | |
| Allergan, INC. | $100.47 | 2020-2021 | |
| Lilly USA, LLC | $100.25 | 2020-2023 | Jardiance, Mounjaro |
| Eisai INC. | $75.76 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $66.30 | 2020-2023 | Rexulti |
| Lundbeck LLC | $60.71 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $52.69 | 2020-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $50.25 | 2021-2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $47.18 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.36 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.54 | 2021-2022 | |
| Antares Pharma, INC. | $34.76 | 2021-2022 | |
| Mylan Specialty L.P. | $34.60 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.44 | 2021-2022 | |
| Amgen INC. | $29.65 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $24.91 | 2021 | |
| Axsome Therapeutics, INC. | $24.29 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $22.76 | 2020 | |
| Nestle Healthcare Nutrition INC. | $19.09 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.81 | 2022 | |
| Medtronic, INC. | $17.51 | 2023 | Venaseal |
| Idorsia Pharmaceuticals US INC | $17.46 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $15.98 | 2023 | Nexletol |
| Exact Sciences Corporation | $15.40 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $14.95 | 2020 | |
| Paratek Pharmaceuticals, INC. | $14.12 | 2020 | |
| Baxter Healthcare | $13.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.